Funzoren 50 mg powder for concentrate for solution for infusion Մալթա - անգլերեն - Malta Medicines Authority

funzoren 50 mg powder for concentrate for solution for infusion

vocate pharmaceuticals s.a 150, gounari str, 166 74 glyfada, athens, greece - micafungin sodium - powder for concentrate for solution for infusion - micafungin sodium 10 mg/ml - antimycotics for systemic use

Mycamine Եվրոպական Միություն - անգլերեն - EMA (European Medicines Agency)

mycamine

astellas pharma europe b.v. - micafungin - candidiasis - antimycotics for systemic use - mycamine is indicated for:adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.the decision to use mycamine should take into account a potential risk for the development of liver tumours. mycamine should therefore only be used if other antifungals are not appropriate.

MICAFUNGIN 100 mg ADCO POWDER Հարավաֆրիկյան Հանրապետություն - անգլերեն - South African Health Products Regulatory Authority (SAHPRA)

micafungin 100 mg adco powder

adcock ingram critical care (pty) ltd - powder - 100,0 mg - each vial contains micafungin sodium equivalent to micafungin 100,0 mg

Mycamine Նոր Զելանդիա - անգլերեն - Medsafe (Medicines Safety Authority)

mycamine

seqirus (nz) ltd - micafungin 50mg - powder for injection - 50 mg - active: micafungin 50mg excipient: citric acid lactose nitrogen sodium hydroxide - treatment of invasive candidiasis in children & adults treatment of oesophageal candidiasis in adults, adolescents nlt 16 yrs of age, and elderly patients for whom intravenous therapy is appropriate prophylaxis of candida infection in children and adult patients undergoing allogenic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count below 500 cells per microliter) for 10 or more days